{"filing":{"accession_number":"0001437749-26-021504","cik":"0002030617","ticker":"PMI","company_name":"Picard Medical, Inc.","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"pmi20260618_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2030617/000143774926021504/pmi20260618_8k.htm"},"events":[{"id":13372,"run_id":11876,"accession_number":"0001437749-26-021504","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Richard Fang, Ph.D. was appointed as Interim CEO effective June 18, 2026, following the planned departure of Patrick NJ Schnegelsberg. Dr. Fang will receive an annual salary of $400,000 and brings relevant executive experience to the role.","company_name":"Picard Medical, Inc.","ticker":"PMI","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10497,"accession_number":"0001437749-26-021504","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses two executive events: the departure of Patrick NJ Schnegelsberg as CEO and Board member effective June 18, 2026, and the appointment of Richard Fang, Ph.D. as Interim CEO effective the same date. While both events occur, the principal disclosed action centers on the appointment of Dr. Fang to the CEO role, with detailed background on his qualifications and compensation ($400,000 annual salary). The departure is characterized as a planned leadership transition without disagreement, making the appointment the salient event. This is material as it represents a change in the Company's chief executive officer.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T11:46:39.829827+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10498,"accession_number":"0001437749-26-021504","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Patrick NJ Schnegelsberg stepped down as Chief Executive Officer and Board member effective June 18, 2026. While the filing also discloses Richard Fang's appointment as Interim CEO, the principal disclosed action centers on the CEO's departure. The departure of a sitting CEO is material to investors assessing leadership continuity and company direction, particularly at a medical device company with a single flagship product.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T11:46:39.829827+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10497,"accession_number":"0001437749-26-021504","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses two executive events: the departure of Patrick NJ Schnegelsberg as CEO and Board member effective June 18, 2026, and the appointment of Richard Fang, Ph.D. as Interim CEO effective the same date. While both events occur, the principal disclosed action centers on the appointment of Dr. Fang to the CEO role, with detailed background on his qualifications and compensation ($400,000 annual salary). The departure is characterized as a planned leadership transition without disagreement, making the appointment the salient event. This is material as it represents a change in the Company's chief executive officer.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T11:46:39.829827+00:00","company_name":"Picard Medical, Inc.","ticker":"PMI","filing_date":"2026-06-24"},{"id":10498,"accession_number":"0001437749-26-021504","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Patrick NJ Schnegelsberg stepped down as Chief Executive Officer and Board member effective June 18, 2026. While the filing also discloses Richard Fang's appointment as Interim CEO, the principal disclosed action centers on the CEO's departure. The departure of a sitting CEO is material to investors assessing leadership continuity and company direction, particularly at a medical device company with a single flagship product.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T11:46:39.829827+00:00","company_name":"Picard Medical, Inc.","ticker":"PMI","filing_date":"2026-06-24"}]}